This study is testing a new treatment called Lenti-HPV-07 for people with cervical or oropharyngeal (throat) cancer caused by Human Papilloma Virus (HPV). Researchers want to see if Lenti-HPV-07 is safe and if it can trigger an immune response in your body. You would receive either one or two intramuscular (IM) injections of Lenti-HPV-07. To join, you need to have HPV-related cervical or oropharyngeal cancer that has been confirmed by a biopsy, and generally be in good health. The study is no longer enrolling participants with recurrent or metastatic (cancer that has spread) cancer, but may still be enrolling those with newly diagnosed, locally advanced cancer. After treatment, you would be followed for up to one year to check on your health.

Study design

This study is an interventional trial planning to enroll 72 participants. Participants will be assigned to a group based on their cancer type.

What's involved

You would receive either one or two intramuscular injections of Lenti-HPV-07. After treatment, you would have follow-up visits or phone calls for up to one year.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 12 months after their last injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.